全文获取类型
收费全文 | 7590篇 |
免费 | 383篇 |
国内免费 | 35篇 |
专业分类
耳鼻咽喉 | 52篇 |
儿科学 | 110篇 |
妇产科学 | 47篇 |
基础医学 | 925篇 |
口腔科学 | 155篇 |
临床医学 | 404篇 |
内科学 | 2185篇 |
皮肤病学 | 80篇 |
神经病学 | 568篇 |
特种医学 | 357篇 |
外科学 | 1289篇 |
综合类 | 22篇 |
预防医学 | 129篇 |
眼科学 | 103篇 |
药学 | 433篇 |
中国医学 | 7篇 |
肿瘤学 | 1142篇 |
出版年
2023年 | 57篇 |
2022年 | 47篇 |
2021年 | 189篇 |
2020年 | 104篇 |
2019年 | 146篇 |
2018年 | 186篇 |
2017年 | 142篇 |
2016年 | 189篇 |
2015年 | 194篇 |
2014年 | 239篇 |
2013年 | 292篇 |
2012年 | 436篇 |
2011年 | 513篇 |
2010年 | 285篇 |
2009年 | 219篇 |
2008年 | 401篇 |
2007年 | 411篇 |
2006年 | 458篇 |
2005年 | 437篇 |
2004年 | 475篇 |
2003年 | 458篇 |
2002年 | 423篇 |
2001年 | 149篇 |
2000年 | 152篇 |
1999年 | 140篇 |
1998年 | 104篇 |
1997年 | 83篇 |
1996年 | 76篇 |
1995年 | 85篇 |
1994年 | 50篇 |
1993年 | 60篇 |
1992年 | 92篇 |
1991年 | 83篇 |
1990年 | 78篇 |
1989年 | 101篇 |
1988年 | 51篇 |
1987年 | 46篇 |
1986年 | 57篇 |
1985年 | 43篇 |
1984年 | 39篇 |
1983年 | 37篇 |
1982年 | 10篇 |
1981年 | 25篇 |
1980年 | 17篇 |
1979年 | 22篇 |
1978年 | 9篇 |
1973年 | 9篇 |
1972年 | 10篇 |
1971年 | 9篇 |
1967年 | 10篇 |
排序方式: 共有8008条查询结果,搜索用时 15 毫秒
1.
Hiroki Teragawa Chikage Oshita Yuichi Orita Kunihiro Hashimoto Hirofumi Nakayama Yuto Yamazaki Hironobu Sasano 《World Journal of Clinical Cases》2021,9(5):1119-1126
BACKGROUNDAdrenal incidentaloma (AI) has been frequently encountered in the clinical setting. It has been shown that primary aldosteronism (PA) or subclinical Cushing’s syndrome (SCS) are the representative causative diseases of AI. However, the coexistence of PA and SCS has been reportedly observed. Recently, we encountered a case of AI, in which PA and SCS coexisted, confirmed by histopathological examinations after a laparoscopic adrenalectomy. We believe that there were some clinical implications in the diagnosis of the present case.CASE SUMMARYA 58-year-old man presented with lower right abdominal pain with a blood pressure of 170/100 mmHg. A subsequent computed tomography scan revealed right ureterolithiasis, which was the cause of right abdominal pain, and right AI measuring 22 mm × 25 mm. After the disappearance of right abdominal pain, subsequent endocrinological examinations were performed. Aldosterone-related evaluations, including adrenal venous sampling, revealed the presence of bilateral PA. In addition, several cortisol-related evaluations showed the presence of SCS on the right adrenal adenoma. A laparoscopic right adrenalectomy was then performed. The histopathological examination of the resected right adrenal revealed the presence of a cortisol-producing adenoma, while CYP11B2 immunoreactivity was absent in this adenoma. However, in the adjacent non-neoplastic adrenal, multiple CYP11B2-positive adrenocortical micronodules were detected, showing the presence of aldosterone-producing adrenocortical micronodules. CONCLUSIONCareful clinical and pathological examination should be performed when a patient harboring AI presents with concomitant SCS and PA. 相似文献
2.
3.
4.
5.
Hirokazu Miki Shingen Nakamura Masahiro Oura Hirofumi Hamano Kenji Ikuta Naoto Okada Yasunobu Okamoto Kimiko Sogabe Mamiko Takahashi Masami Iwasa Kengo Udaka Takeshi Harada Kiyoe Kurahashi Shiro Fujii Sumiko Yoshida Kumiko Kagawa Itsuro Endo Ken-ichi Aihara Masahiro Abe 《British journal of haematology》2019,186(2):355-358
6.
7.
8.
9.
10.
Naoko Shoji Keiji Tanese Ayano Sasaki Taishi Horiuchi Yuji Utsuno Koichi Fukuda Yukiko Hoshino Shinichi Noda Hirofumi Minami Wataru Asakura Amenamevir Review Team 《The Journal of dermatology》2020,47(7):683-688
In July 2017, Japan’s Ministry of Health, Labor and Welfare issued a marketing authorization valid throughout Japan for N-(2,6-dimethylphenyl)-N-(2-{[4-(1,2,4-oxadiazol-3-yl)phenyl]amino}-2-oxoethyl)-1,1-dioxothiane-4-carboxamide (amenamevir) for the first time worldwide. The decision was based on the favorable opinion of the Pharmaceuticals and Medical Device Agency (PMDA) recommending a marketing authorization of amenamevir for treatment of herpes zoster (HZ). Amenamevir has a different action mechanism from previously approved synthetic nucleoside compounds for the treatment of HZ including acyclovir, valacyclovir and famciclovir. The usual adult dose is 400 mg amenamevir p.o. once daily for 7 days. The benefit is its ability to cure HZ as well as preventing postherpetic neuralgia. The most common side-effects are increase of urine N-acetyl-β-D-glucosaminidase and α1-microglobulin levels. However, based on the detailed evaluation of the submitted clinical studies, there seems to be no serious safety concerns about amenamevir regarding the kidney of both renally normal and impaired patients. The objective of this article is to summarize the scientific review of the application. The detailed scientific assessment report and product information, including the summary of product characteristics, are available on the PMDA website ( www.pmda.go.jp/PmdaSearch/iyakuSearch/ ). 相似文献